Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARROS-1 study of zidesamtinib in ROS1-positive advanced solid tumors
NL-OMON58757Phase 2Recruiting
- Sponsor
- Nuvalent
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of zidesamtinib in non-small cell lung cancer (NSCLC) and Nonhematologic neoplasms (6 arms), sponsored by Nuvalent. Primary endpoints: Recommended phase 2 dose and maximum tolerated dose and Objective response rate. Started May 2022; status: recruiting.
02
Drugs
zidesamtinib
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON58757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58757.